201 related articles for article (PubMed ID: 3274451)
1. Potent immunosuppression overcomes retransplantation, presensitization, and historical positive crossmatch as transplant risk factors.
Gaber AO; Thistlethwaite JR; Haag BW; Stuart J; Mayes J; Fellner S; Stuart FP
Transplant Proc; 1987 Feb; 19(1 Pt 3):1915-6. PubMed ID: 3274451
[No Abstract] [Full Text] [Related]
2. Cox regression analysis of outcome risk factors in 519 renal allograft recipients.
Canafax DM; Savik SK; Draxler CA; Le CT; Ascher NL; Payne WD; Sutherland DE; Migliori RJ; Simmons RL; Najarian JS
Transplant Proc; 1987 Feb; 19(1 Pt 3):1947-8. PubMed ID: 3274455
[No Abstract] [Full Text] [Related]
3. High rate of success in kidney cadaveric retransplantation with optimal matching and potent immunosuppression.
Hiesse C; Neyrat N; Busson M; Bensadoun H; Lantz O; Bellamy J; Benoit G; Charpentier B; Fries D
Transplant Proc; 1990 Aug; 22(4):1909-10. PubMed ID: 2389483
[No Abstract] [Full Text] [Related]
4. Positive B cell crossmatches in highly sensitized patients--influence of antibody specificity on renal transplant outcome.
Lazda VA; Pollak R; Mozes MF; Jonasson O
Transplant Proc; 1987 Feb; 19(1 Pt 1):782-4. PubMed ID: 3547840
[No Abstract] [Full Text] [Related]
5. Triple immunosuppressive therapy in immunologic high-risk renal allograft recipients.
Cole E; Robinson C; Bear R
Transplant Proc; 1989 Feb; 21(1 Pt 2):2026-7. PubMed ID: 2652662
[No Abstract] [Full Text] [Related]
6. Cadaveric renal transplantation after pulsatile perfusion, histocompatibility matching, and conversion to cyclosporine therapy.
Milgrom M; Kyriakides GK; Esquenazi V; Olson L; Miller J
Transplant Proc; 1987 Feb; 19(1 Pt 3):1873. PubMed ID: 3274444
[No Abstract] [Full Text] [Related]
7. Tolerance induction in human kidney retransplantation: impact of repeated HLA mismatches in 156 second renal grafts.
Gnant MF; Sautner T; Rosenmayr A; Muehlbacher F
Transplant Proc; 1993 Feb; 25(1 Pt 1):319-21. PubMed ID: 8438317
[No Abstract] [Full Text] [Related]
8. Quadruple therapy for cadaver renal transplantation.
Deierhoi MH; Sollinger HW; Kalayoglu M; Belzer FO
Transplant Proc; 1987 Feb; 19(1 Pt 3):1917-9. PubMed ID: 3274452
[No Abstract] [Full Text] [Related]
9. A comparison of three immunosuppressive protocols in patients aged over 50 years.
Fryd DS; So SK; Kruse L; Canafax DM; Sutherland DE; Simmons RL; Najarian JS
Transplant Proc; 1987 Feb; 19(1 Pt 2):1530-1. PubMed ID: 3274374
[No Abstract] [Full Text] [Related]
10. Intermodal immunosuppression for cadaver renal transplantation: results using antilymphocyte globulin, azathioprine, cyclosporine, and prednisone.
Halloran P; Ludwin D; Bear R; Aprile M; McQuarrie B; Poole R; White N
Transplant Proc; 1987 Feb; 19(1 Pt 3):1931-2. PubMed ID: 3274454
[No Abstract] [Full Text] [Related]
11. Effect of DR and DR6 matching on cadaver kidney transplant survival.
Reyman TA; Toledo-Pereyra LH
Transplant Proc; 1987 Feb; 19(1 Pt 1):702-4. PubMed ID: 3274848
[No Abstract] [Full Text] [Related]
12. Strategy for improving retransplantation in the CyA era.
Dickerman R; Langley J; Brinker K; Trevino G; Melton L; Vergne-Marini P; Wilson PK
Transplant Proc; 1993 Feb; 25(1 Pt 1):257-8. PubMed ID: 8438292
[No Abstract] [Full Text] [Related]
13. An immunosuppressive protocol compatible with the United States kidney transplant diagnosis related grouping.
Stuart FP; Stuart JK; Thistlethwaite JR; Gaber AO; Mayes J
Transplant Proc; 1987 Feb; 19(1 Pt 3):1959-60. PubMed ID: 3152656
[No Abstract] [Full Text] [Related]
14. The results of renal transplantation with cyclosporine in immunologically high-risk patients.
Dickerman RM; Vergne-Marini P; Langley J; Trevino G; Velez R; Brinker K; Nesser D; Long D; Hull AR
Transplant Proc; 1987 Feb; 19(1 Pt 3):1846-8. PubMed ID: 3079047
[No Abstract] [Full Text] [Related]
15. Effect of duration of MALG therapy in a quadruple immunosuppressive protocol.
Stratta RJ; D'Alessandro AM; Armbrust MJ; Pirsch JD; Sollinger HW; Kalayoglu M; Belzer FO
Transplant Proc; 1989 Feb; 21(1 Pt 2):1726-8. PubMed ID: 2652564
[No Abstract] [Full Text] [Related]
16. Potent immunosuppression overcomes immunologic high-risk factors in recipients of cadaveric renal allografts.
Gaber AO; Thistlethwaite JR; Haag BW; Stuart JK; Mayes JT; Lloyd DM; Fellner S; Stuart FP
Am Surg; 1987 Jul; 53(7):407-9. PubMed ID: 3300451
[TBL] [Abstract][Full Text] [Related]
17. A controlled trial comparing sequential antilymphocyte sera and cyclosporine therapy to conventional therapy in renal transplant recipients.
Cardella CJ; Harding ME; deVeber GA; Honey J; Cook GT
Transplant Proc; 1987 Feb; 19(1 Pt 3):1996-7. PubMed ID: 3079065
[No Abstract] [Full Text] [Related]
18. Pediatric renal transplantation results are improved with triple drug therapy with cyclosporine, azathioprine, and prednisone.
MacDonell RC; Johnson K; Richie R; Nylander W; McMahon Y; Niblack G; Green W; Morrissey J; Ynares C
Transplant Proc; 1989 Feb; 21(1 Pt 2):1701-4. PubMed ID: 2652557
[No Abstract] [Full Text] [Related]
19. A flexible immunosuppression protocol for organ transplantation using cyclosporine, azathioprine, and prednisone.
Schweizer RT; Rovelli M; Roper L; Bartus SA
Transplant Proc; 1987 Feb; 19(1 Pt 3):1944-6. PubMed ID: 3079062
[No Abstract] [Full Text] [Related]
20. Trends in immunosuppression for kidney transplantation.
Butt KM; Zielinski CM; Parsa I; Elberg AJ; Wechter W; Kountz SL
Kidney Int Suppl; 1978 Jun; (8):S95-8. PubMed ID: 357820
[No Abstract] [Full Text] [Related]
[Next] [New Search]
